Novavax Reports Vaccine 90% Effective; Supply Questions Remain

Another highly effective vaccine is poised to join the fight against COVID-19.  

But its impact may be blunted by supply issues. The manufacturer expected to produce the bulk of the doses is in India, where the government has banned vaccine exports.   Biotech company Novavax announced Monday that its vaccine was 100% effective in preventing severe cases of COVID-19 and 90% effective in preventing any form of the disease in a clinical trial in the United States and Mexico.  The company has an agreement to sell 350 million doses to COVAX, the World Health Organization-backed program to improve equitable vaccine access globally. It expects to start delivering shots in the third quarter of 2021, pending approval from regulators.